What should I pay attention to when taking Valsartan Capsules

Valsartan capsules are mainly used to treat mild and moderate hypertension. Because many people nowadays do not understand and know the use of medications, they often use them indiscriminately in terms of dosage. As a result, because they do not pay attention to age and gender issues, patients do not have clear effects after taking the medication. Generally, the therapeutic effect of this product should be about four weeks, and the maximum effect can be achieved after four weeks. If you are not satisfied, you can increase the dosage. Before increasing the dosage, you need to consult the doctor who prescribes the medicine. It should be noted that this product may also have some side effects, which will cause patients with hypertension to often feel weak, feel like resting, have no strength, and be unclear in the mind after taking the medicine. Most of this phenomenon will be relieved after a period of sleep. It is mainly caused by the medication interfering with the body's hormones. For some patients with renal function diseases, do not take this product easily at ordinary times.

Main Benefits

Suitable for mild and moderate essential hypertension.

Dosage

Recommended dose: 80 mg of this product, once a day. The dose was not related to race, age, or gender. It may be taken with or without food (see Absorption). It is recommended to take the medication at the same time each day (such as in the morning).

The medication can achieve a definite antihypertensive effect within 2 weeks and the maximum therapeutic effect after 4 weeks. If the antihypertensive effect is unsatisfactory, the daily dose can be increased to 160 mg, or a diuretic can be added.

No dose adjustment is required for patients with renal impairment (contraindications are seen in severe renal failure) and non-biliary, non-choledostatic hepatic impairment.

Valsartan can be used in combination with other antihypertensive drugs.

Generic Name: Valsartan Capsules

Product Name:

English name: Valsartan Capsules

Chemical composition

The active ingredient of this product is valsartan.

Drug interactions

No significant drug interactions were found clinically.

The following drugs have been studied: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, and glyburide.

Since valsartan is hardly metabolized, no clinical interactions have been found with related drugs in terms of inducing or inhibiting the cytochrome P450 system. Although valsartan is largely bound to plasma proteins, in vitro experiments have not found any interaction with other plasma protein-bound drugs (such as diclofenac, furosemide, and warfarin) at this level.

When used in combination with potassium-sparing diuretics (such as spironolactone, triamterene, amiloride), potassium supplementation or the use of potassium-containing preparations may lead to

Pharmacological Action

This product is an antagonist of angiotensin II (AngII) receptor AT1. It inhibits vasoconstriction and the release of aldosterone by selectively blocking the binding of AngII to AT1 receptor, thus producing a hypotensive effect.

Additional Information

【store】

Keep sealed, valid for 2 years.

[Validity period]

Tentative 24 months

Adverse Reactions

In a placebo- and Diovan-controlled trial in 2,316 hypertensive patients, the overall incidence of adverse events (AEs) in the Diovan group was similar to that in the placebo group.

In a 6-month open-label extension trial of 642 hypertensive patients treated with 320 mg of valsartan, the overall incidence of adverse events was similar to that observed in the placebo-controlled trials.

The table below shows the incidence of adverse reactions reported in 10 placebo-controlled trials in which patients received valsartan 10-320 mg/day for up to 12 weeks. Among the 2316 patients, 1281 and 660 took 80 mg and 160 mg respectively. The incidence of adverse reactions seen has nothing to do with the dosage and duration of medication.

Drug contraindications

Patients who are allergic to valsartan or any other excipients in this product. Pregnancy (see [Use in Pregnant and Lactating Women])

Precautions

Low sodium and/or hypovolemia

In rare cases, patients with severe sodium deficiency and/or hypovolemia (e.g., high-dose diuretic use) may experience symptomatic hypotension when starting treatment with this product. Hyponatremia and/or hypovolemia should be corrected or the diuretic dose should be reduced before medication is started. If hypotension occurs, the patient should be placed in a supine position and, if necessary, given intravenous saline. Resume treatment with this drug after blood pressure stabilizes.

Renal artery stenosis

Short-term use of this drug in 12 patients with secondary renovascular hypertension caused by unilateral renal artery stenosis did not cause significant changes in renal hemodynamics, creatinine, and urea nitrogen (BUN). Because other drugs that act on the RAAS may increase BUN and creatinine in patients with unilateral or bilateral renal artery stenosis, monitoring of BUN and creatinine is recommended as a safety measure.

Renal insufficiency

No dosage adjustment is required in patients with renal impairment. However, since there is no data on severe cases (creatinine clearance <10ml/min), caution is required when using it.

Hepatic insufficiency

No dosage adjustment is required in patients with hepatic impairment.

Valsartan is mainly excreted in the bile in its original form, and excretion is reduced in patients with biliary obstruction (see [Pharmacokinetics]). Therefore, special caution should be exercised when using valsartan in such patients. Effects on driving and operating machines As with other antihypertensive drugs, patients taking this drug should be careful when driving or operating machines.